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Purpose: Evaluate long-term outcomes after one, two, or three trabecular micro-bypass 
stents implanted in a standalone procedure in eyes with open-angle glaucoma taking ocular 
hypotensive medication.
Patients and methods: Prospective randomized ongoing study of 119 subjects (109 with 
42-month follow-up) with open-angle glaucoma, preoperative intraocular pressure (IOP) 
18–30 mmHg on one to three glaucoma medications, and unmedicated (post-washout) IOP 
22–38 mmHg. Subjects were randomized to receive one (n=38), two (n=41), or three (n=40) 
iStent trabecular micro-bypass stents in a standalone procedure. Postoperatively, IOP was 
measured with medication and annually following washout. Data included IOP, medications, 
gonioscopy, pachymetry, visual field, visual acuity, adverse events, and slit-lamp and fundus 
examinations.
Results: Preoperative mean medicated IOP was 19.8±1.3 mmHg on 1.71 medications in 
one-stent eyes, 20.1±1.6 mmHg on 1.76 medications in two-stent eyes, and 20.4±1.8 mmHg 
on 1.53 medications in three-stent eyes. Post-washout IOP prior to stent implantation was 
25.0±1.2, 25.0±1.7, and 25.1±1.9 mmHg in the three groups, respectively. Postoperatively, 
Month 42 medicated IOP was 15.0±2.8, 15.7±1.0 and 14.8±1.3 mmHg in the three groups, and 
post-washout IOP (Months 36–37) was 17.4±0.9, 15.8±1.1 and 14.2±1.5 mmHg, respectively. 
IOP reduction 20% without medication was achieved in 89%, 90%, and 92% of one-, two-, 
and three-stent eyes, respectively, at Month 12; and in 61%, 91%, and 91% of eyes, respectively, 
at Month 42. The need for additional medication remained consistent at Months 12 and 42 in 
multi-stent eyes (four two-stent eyes and three three-stent eyes at both time points), whereas 
it increased in single-stent eyes (four eyes at Month 12 versus 18 eyes at Month 42). Safety 
parameters were favorable in all groups.
Conclusion: The standalone implantation of either single or multiple iStent® device(s) produced 
safe, clinically meaningful IOP and medication reductions through 42 months postoperatively, 
with incrementally greater and more sustained reductions in multi-stent eyes.
Keywords: microinvasive glaucoma surgery/MIGS, iStent, surgery, standalone, multiple
Introduction
The treatment of glaucoma, a leading cause of irreversible blindness globally, may 
include a spectrum of medical and/or surgical interventions. Most treatments aim to 
lower intraocular pressure (IOP), which is widely established as the primary modifi-
able risk factor for onset and progression of glaucoma. In most clinical practices, 
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patients in the early stages of open-angle glaucoma (OAG) 
are first prescribed topical medications. As the next treatment 
step, patients often undergo laser trabeculoplasty, but due 
to disease progression and/or the well-documented waning 
efficacy of laser trabeculoplasty over time, this intervention 
frequently is not a long-term solution.
For patients with mild-to-moderate glaucoma that pro-
gresses despite medications and/or laser procedures, there 
has been, until recently, a paucity of viable intermediate 
surgical options. Thus, these patients have often been advised 
to undergo watchful waiting until the glaucomatous damage 
reached an extent that made the risk-to-benefit profile of 
traditional filtering surgeries more acceptable. Such risks 
of traditional filtering surgeries could include, for example, 
endophthalmitis, fibrosis, bleb leaks or infections, bleb dys-
esthesia, and hypotony maculopathy; and many of the risks 
remain throughout life, contributing to a lifelong cumulative 
postoperative burden for the patient.1–10
The above treatment gap between early and advanced 
glaucoma has decreased substantially in the past decade with 
the introduction and increasing adoption of micro-invasive 
glaucoma surgery (MIGS) procedures. The first US Food and 
Drug Administration-approved MIGS device was the iStent,® 
a trabecular micro-bypass stent (Glaukos Corporation, San 
Clemente, CA, USA). To date, the first-generation iStent and 
the second-generation iStent inject® (Glaukos Corporation) 
have been the subject of over 65 peer-reviewed research pub-
lications. Most initial studies of these technologies were in 
OAG patients undergoing concomitant cataract surgery,11–20 
while several more recent publications have evaluated 
standalone implantation of single or multiple iStent or iStent 
inject devices in OAG.21–31 In both settings, study results have 
consistently shown durable long-term ability to lower IOP 
and medications in patients with OAG and in pseudoexfolia-
tive glaucoma. Such findings suggest that reduced IOP and 
medication burden indeed may be achieved by a minimally 
invasive approach. Moreover, these reductions have been 
accompanied by a favorable safety profile, thereby differen-
tiating these procedures from the risks of traditional filtering 
surgeries such as those discussed previously.1–10
In the present study, the authors examined the long-term 
safety and IOP- and medication-reducing effects of implant-
ing one, two, or three first-generation iStent trabecular 
micro-bypass stents in a standalone procedure in eyes with 
OAG not controlled on ocular hypotensive medication(s). 
Outcomes through 18 months were presented in a prior 
publication.31 Briefly, the prior report showed substantial IOP 
reduction after implantation of one iStent; each additional 
stent incrementally added more IOP reduction. Likewise, the 
implantation of additional stents resulted in higher propor-
tions of eyes achieving 20% IOP reduction without medi-
cation at 12 months, as well as IOP 18 and 15 mmHg 
without medication at 12 months.31 Through 18 months, 
fewer multiple-stent versus single-stent eyes required the 
addition of ocular hypotensive medication. Based on this 
earlier publication, the present report summarizes data 
through 42 months postoperative; subjects will continue to 
be followed for a total of 60 months.
Materials and methods
study design
This study is a prospective, randomized, open-label evalu-
ation of the long-term safety and performance of one, two, 
or three iStent trabecular micro-bypass stents implanted in 
a standalone procedure (ie, without cataract surgery) in eyes 
with OAG. As presented in the prior publication, participat-
ing surgeons in this study included five visiting MIGS Study 
Group surgeons from four countries (USA, Italy, Germany, 
and Spain), in addition to one staff surgeon (Armenia).31 Sur-
geons received training on the iStent implantation technique 
and the study protocol prior to their study participation. All 
surgeries and follow-up visits were completed at the S.V. 
Malayan Ophthalmological Center in Yerevan, Armenia; the 
Armenian Ministry of Health provided Ethics Committee 
approval. The study followed the tenets of the Declaration 
of Helsinki (2008); all participating subjects provided writ-
ten informed consent. The study registration number is NCT 
01517477 (ClinicalTrials.gov).
The study design specified enrollment of up to 120 phakic 
or pseudophakic subjects with OAG, cup-to-disc (C:D) 
ratio 0.9, current treatment with one to three medications, 
preoperative medicated IOP of 18–30 mmHg, and preopera-
tive unmedicated (post-washout) IOP of 22–38 mmHg. The 
complete inclusion and exclusion criteria were presented in 
the prior publication.31 Postoperatively, the subjects were 
examined at Day 1, Week 1, and at Months 1, 3, 6, 12, 13, 
18, 24, 25, 30, 36, 37, and 42; subjects are continuing to 
be followed for a total of 60 months. Postoperative perfor-
mance was evaluated based on IOP (by Goldmann applana-
tion tonometry) and ocular hypotensive medication use. 
At each annual postoperative visit, any subject taking an 
ocular hypotensive medication began a 1-month medication 
washout, which was followed by unmedicated examinations 
at Months 13, 25, and 37. For continuous variables such 
as IOP and medications at each visit, descriptive analyses 
included mean and SD. Additional calculations included the 
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proportion of eyes with IOP reduced 20% versus baseline 
without medication at Month 12 and Month 42; proportions 
of eyes with Month 42 best-corrected visual acuity (BCVA) 
equal to or better than 20/40, 20/100, and 20/200; and a 
Kaplan–Meier plot showing postoperative time to addition 
of medication. In addition to BCVA, safety measures in all 
eyes included visual field (VF); pachymetry; findings from 
slit-lamp, gonioscopic, and fundus examinations (including 
optic nerve assessment and C:D ratio); and intraoperative and 
postoperative adverse events. Examinations were completed 
by the staff surgeon and glaucoma-trained staff ophthalmolo-
gists at the S.V. Malayan Ophthalmological Center. The total 
duration of study follow-up was fixed at 5 years.
surgical devices and technique
Study subjects underwent implantation of one, two, or three 
iStent trabecular micro-bypass stents in a sole procedure. Each 
single-piece, heparin-coated, titanium stent has a length of 
1.0 mm, height of 0.33 mm, and a “snorkel” bore diameter 
of 120 µm. Figure 1 shows the stent, which is pre-loaded on 
a single-use inserter that is advanced ab internally through 
a small temporal clear corneal incision, thereby preserving 
ocular tissue in case other glaucoma surgery is needed in the 
future. The inserter is designed to facilitate stent implantation 
into Schlemm’s canal, thereby bypassing the nasal trabecular 
meshwork, in order to improve natural physiologic aqueous 
outflow and reduce IOP. In subjects randomized to receive two 
or three stents in this study, a second iStent (and third iStent, 
if applicable) was implanted in the same manner ~2–3 clock 
hours away from the already-implanted stent(s).
After surgery, the subjects were placed on topical anti-
biotic medication for 1 week and a topical corticosteroid 
taper for 4 weeks. Postoperative glaucoma medication was 
started if IOP exceeded 18 mmHg or in the case of concerning 
optic nerve or VF changes; any such medication was stopped 
during annual 1-month medication washouts. The choice 
of 18 mmHg as the IOP cut-off was consistent with the 
finding of the landmark Advanced Glaucoma Intervention 
Study (AGIS) that VF progression is delayed when IOP is 
consistently maintained below 18 mmHg.32
Results
iOP and medications
A total of 119 qualified subjects were randomized to undergo 
implantation of one, two, or three stents (n=38, 41, and 40 
in the three groups, respectively); follow-up data through 
42 months are available for 109 of these subjects (n=33, 
38, and 38 in the three groups, respectively). The prior 
publication from this study provided the complete preop-
erative demographics and ocular parameters of subjects 
in this study.31 In the one-, two-, and three-stent groups, 
preoperative mean medicated IOP was 19.8±1.3 mmHg 
(range, 18–24 mmHg) on a mean of 1.71 medications, 
20.1±1.6 mmHg (range, 18–25 mmHg) on a mean of 1.76 
medications, and 20.4±1.8 mmHg (range, 18–28 mmHg) on 
a mean of 1.53 medications, respectively. Post-washout mean 
IOP before stent implantation was 25.0±1.2 mmHg (range, 
23–28 mmHg), 25.0±1.7 mmHg (range, 22–30 mmHg), and 
25.1±1.9 mmHg (range, 22–32 mmHg) for the three respec-
tive groups. All but two subjects were phakic.
At Month 42 postoperatively, mean medicated IOP had 
decreased to 15.0±2.8 mmHg (range, 10.7–19.7 mmHg), 
15.7±1.0 mmHg (range, 12.0–17.3 mmHg), and 14.8± 
1.3 mmHg (range, 12.0–16.7 mmHg) in the three groups, 
respectively, reflecting 24%, 22%, and 27% reductions 
versus preoperative mean medicated IOP, respectively 
(Figure 2). In the absence of medication (ie, post-washout at 
Month 36–37), mean unmedicated IOP was 17.4±0.9 mmHg 
(range, 14.7–19.3 mmHg), 15.8±1.1 mmHg (range, 13.7–
18.0 mmHg), and 14.2±1.5 mmHg (range, 11.7–17.7 mmHg) 
Figure 1 istent® trabecular micro-bypass.
Notes: istent®; glaukos Corporation, san Clemente, Ca, Usa.





for one-, two-, and three-stent eyes, respectively, constituting 
reductions of 30%, 37%, and 43%, respectively, versus pre-
operative unmedicated IOP. As shown in Figure 3, postopera-
tive IOP reduction 20% without medication was achieved 
in 89%, 90%, and 92% of one-, two-, and three-stent eyes, 
respectively, at Month 12; and in 61%, 91%, and 91% of eyes 
in the three groups, respectively, at Month 42.
Per the study design, all subjects were on one to three 
medications preoperatively (specific mean values were 1.71, 
1.76, and 1.53 medications for the three groups, respectively), 
and all subjects were placed on zero medications immediately 
after surgery. Over 42 months of follow-up, medication was 
added if IOP exceeded 18 mmHg or in cases of glaucoma-
tous optic nerve or VF changes. By Month 42, among eyes 
without additional surgery, postoperative medication was 
added in a total of 18 eyes in the one-stent group, four eyes 
in the two-stent group, and three eyes in the three-stent group. 
In particular, the need for additional medication remained 
stable in multi-stent eyes (four two-stent eyes and three three-
stent eyes at both Months 12 and 42) whereas it increased in 
single-stent eyes (four eyes at Month 12 versus 18 eyes at 
Month 42), as shown in Figure 4.
safety assessment
No complications occurred intraoperatively or periopera-
tively, including no hypotony, choroidal effusion, hyphema, 
nor iridodialysis. During 42 months of postoperative fol-
low-up, no device-related or sight-threatening adverse events 
Figure 2 Mean iOP over time.a
Notes: aexcludes data after cataract surgery. *M12–13 iOP includes M12 iOP of eyes taking 0 medications, plus M13 post-washout iOP of eyes that had been on medications. 
M24–25 and M36–37 iOP values are similar.
Abbreviations: Bl, baseline; iOP, intraocular pressure; M, month; sCr, screening.
Figure 3 Proportional analysis of postoperative iOP reduction 20% without medication at months 12 and 42.a
Note: aexcludes data after cataract surgery.
Abbreviations: iOP, intraocular pressure; M, month.
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occurred; furthermore, no eyes required additional glaucoma 
surgery. In this cohort of almost entirely phakic subjects (117 
of 119) with mean baseline age between 62 and 69 years, the 
most common (and expected) adverse event over 3.5 years 
of follow-up was progression of preexisting cataract. By 
Month 42 postoperatively, a total of eight one-stent eyes, 
five two-stent eyes, and seven three-stent eyes had BCVA 
loss 1 line due to cataract progression. Of these cases, 
five one-stent eyes, two two-stent eyes, and three three-stent 
eyes underwent cataract surgery by Month 42, and their IOP 
and medication data thereafter were excluded from efficacy 
analyses; two additional eyes (three-stent group) had cataract 
surgery shortly after the Month 42 visit. In the remaining 
eight non-operated eyes, BCVA still remained relatively high: 
20/25 or 20/29 in seven eyes and 20/40 in one eye at Month 
42. Across all groups, postoperative BCVA appeared gener-
ally stable through Month 42; proportional analysis of Month 
42 BCVA is shown in Figure 5. In addition, mean C:D ratio 
and central corneal thickness remained stable over time in all 
groups through Month 42 (Table 1). Meanwhile, VF mean 
deviation decreased in all three groups from screening through 
Month 42; these reductions were compared between the three 
groups using one-way analysis of variance (ANOVA), and 
were found to be statistically similar (p=0.40, Table 1).
Discussion
The 42-month results from this ongoing randomized study 
demonstrate substantial IOP- and medication-reducing 
effects of one, two, or three trabecular micro-bypass stents 
when implanted as a standalone procedure in eyes with mild-
to-moderate OAG. Similar to the prior publication from 
this cohort,31 as well as a study by Belovay et al of two or 
three iStents during cataract surgery,23 our present findings 
indicate that the largest portion of IOP reduction results from 
the first stent: specifically, a 7.6 mmHg (30%) reduction in 
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Figure 4 Time to addition of postoperative medication.a
Note: aexcludes data after cataract surgery.
Figure 5 Proportional analysis of Month 42 best-corrected visual acuity.





additional stent provided further IOP reduction in an incre-
mental manner: 9.2 mmHg (37%) total IOP decrease with 
two stents, and 10.9 mmHg (43%) total IOP decrease with 
three stents.
In addition to confirming these prior clinical reports, 
the current 42-month IOP findings corroborate data from 
laboratory investigations of incremental efficacy with 
multiple iStent devices.33–36 For example, Hunter et al 
reported 6 mmHg of IOP reduction and 30% decrease in 
outflow resistance after one stent, and 8.9 mmHg and 44% 
decrease, respectively, after two stents.33 Similarly, Bahler 
et al estimated IOP reductions of 6.1 and 9.7 mmHg with 
one and two stents, respectively.34–35 A possible explana-
tion for this stepwise IOP reduction may be drawn from 
the biomechanical models of Johnstone, whose laboratory 
data showed aqueous tissue deformation induced by IOP 
gradients.36 If such tissue alteration were to decrease the 
action of a single trabecular stent, the use of multiple stents 
hypothetically may circumvent this decrease. Thus, in the 
context of these laboratory data as well as the aforementioned 
clinical studies, the 42-month IOP reductions seen in the 
present cohort (30%, 37%, and 43%) appear directionally 
and quantitatively reasonable.
A distinguishing feature of the 42-month findings versus 
those of the prior publication31 is the increased use of medi-
cations in single-stent versus multi-stent eyes over time. 
As before, medication reductions were observed in all three 
groups at all time points, but our current findings suggest 
an increasing divergence in the degree of medication reduc-
tion in single-stent versus multi-stent eyes as time elapsed. 
As shown in Figure 4, the need for additional medication 
appeared to stabilize in multi-stent eyes, with equal numbers 
of subjects on medication at both 12 and 42 months in the 
two groups (four two-stent eyes and three three-stent eyes); 
meanwhile, over the same period, the need for additional 
medication increased in one-stent eyes (four eyes at Month 
12 versus 18 eyes at Month 42). This report covers ~3.5 years 
of postoperative follow-up, so it will be meaningful to 
observe outcomes through study completion at 5 years.
Safety parameters continued to be favorable in all the 
three groups, with no intraoperative or perioperative compli-
cations (including no hypotony, choroidal effusion, hyphema, 
nor iridodialysis); no postoperative device-related or sight-
threatening adverse events; and no additional glaucoma 
surgeries throughout 42 months of follow-up. In addition, 
postoperative BCVA, C:D ratio, and central corneal thick-
ness remained generally stable in all groups through Month 
42 (Figure 5; Table 1). VF mean deviation decreased to a 
similar extent in all the three groups from screening through 
Month 42 (ANOVA p-value =0.40, Table 1). However, it 
must be kept in mind that glaucoma is an inherently pro-
gressive condition, even in the setting of surgical and/or 
medication-induced reductions in IOP. For example, the 
landmark Early Manifest Glaucoma Trial showed that IOP-
lowering treatment decreased, but did not stop, VF progres-
sion. In this cohort, disease progression occurred in both 
untreated (62% of eyes) and treated subjects (45% of eyes), 
despite a mean IOP reduction of 5.1 mmHg.37 Similarly, 
the foundational Collaborative Normal Tension Glaucoma 
Study reported VF progression in 35% of untreated eyes 
(which had no significant IOP reduction), but also in 12% 
of treated eyes (despite their IOP reduction).38 Furthermore, 
the landmark AGIS showed VF decline in both treated and 
untreated eyes, and showed that this decline was progres-
sive over time through seven years postoperatively.32 In this 
cohort of almost entirely phakic subjects, the most common 
(and expected) postoperative adverse event was cataract 
progression. However the cataract rates observed in this study 
were not dissimilar to US population-based estimates, which 
document cataract progression in ~18% to 33% of phakic, 
similarly aged subjects over 3.5 years of follow-up.39 The 
majority of the cataract cases in our study were rectified by 
cataract surgery, and BCVA in the remaining non-operated 
eyes still remained relatively good. Importantly, although 
Table 1 Mean cup-to-disc ratio, central corneal thickness, and 
visual field mean deviation preoperatively and at 42 months post­
operative





C:D ratio mean (sD) 0.68 (0.11) 0.69 (0.11) 0.01
VF MD (dB) mean (sD) −4.72 (4.42) −6.43 (4.95) −1.42a
CCT (µm) mean (sD) 529.0 (33.9) 538.1 (35.7) 1.7% increase
Two-stent group (n=41)
n 41 38
C:D ratio mean (sD) 0.71 (0.14) 0.70 (0.14) −0.01
VF MD (dB) mean (sD) −5.20 (5.65) −7.11 (5.78) −1.26a
CCT (µm) mean (sD) 541.1 (38.3) 548.3 (39.1) 1.3% increase
Three-stent group (n=40)
n 40 38
C:D ratio mean (sD) 0.70 (0.12) 0.70 (0.12) 0
VF MD (dB) mean (sD) −4.81 (4.22) −6.91 (5.40) −2.08a
CCT (µm) mean (sD) 523.3 (37.0) 529.3 (35.2) 1.1% increase
Note: aANOVA between­group comparison of change in visual field MD at M42 
versus screening: p-value =0.40 (not significant).
Abbreviations: anOVa, analysis of variance; C:D, cup-to-disc; CCT, central corneal 
thickness; VF, visual field; MD, mean deviation; M, month; SD, standard deviation.
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multi-stent eyes had undergone a separate insertion for each 
stent, these additional intraocular entries were not associated 
with a higher incidence of complications.
This study is not without limitations. The investigation 
was an open-label, single-site, unmasked study in a solely 
Caucasian patient population. Baseline and postoperative 
IOPs were not measured at multiple time points, leaving open 
the possibility of regression to the mean. No standardized 
cataract grading system nor threshold for completing cataract 
surgery was used. One may notice the relatively low values 
for IOP variance in this study; these appear consistent with 
variance in prior clinical reports.16,17,29 Finally, this report 
encompasses data through 42 months; a future report will 
be able to assess even longer-term outcomes through study 
completion at 60 months.
Limitations notwithstanding, this long-term randomized 
study presents clinically informative data on the standalone 
performance of one, two, and three first-generation trabecular 
micro-bypass stents through 42 months in subjects with mild-
to-moderate OAG not controlled on preoperative medication. 
The data show substantial IOP reduction in all groups and 
incrementally greater IOP reduction in multiple-stent eyes, 
together with an excellent safety profile, thereby confirming 
results of prior clinical and laboratory work.23,31,33–36 Medica-
tion burden also decreased in all groups in an incremental 
manner, consistent with the 18-month findings from this 
study.31 Over 42 months of follow-up, fewer multiple-stent 
versus single-stent eyes ultimately required additional 
postoperative medication, with an apparent stabilization of 
medication in multi-stent eyes versus continued increase in 
single-stent eyes. Thus, these long-term findings corroborate 
the existing literature showing high efficacy with one stent, 
and incrementally greater IOP and medication reductions 
with additional stents.
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